Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jürgen K. Rockstroh"'
Autor:
Martin Gartland, Juan Sierra Madero, Andrea Antinori, Brian Wynne, Jean van Wyk, Pedro Cahn, Keith A. Pappa, Choy Y. Man, Pierre-Marie Girard, Mark R. Underwood, Daisy J. Brandon, Lloyd Curtis, Roberto Ortiz, Jose R. Arribas, Chien-Ching Hung, Jürgen K. Rockstroh, Michael Aboud, Jörg Sievers, Amanda Clarke, Rimgaile Urbaityte, Kimberly Y. Smith
Publikováno v:
AIDS (London, England)
To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2.Desig
Publikováno v:
AIDS (London, England)
Objective: Transplant a liver from an HIV-positive mother to her HIV-negative child to save the child's life. Design: A unique case of living donor liver transplantation from an HIV-positive mother to her HIV-negative child in South Africa. Two aspec
Autor:
Christoph Boesecke, Morten A. Karsdal, Jonel Trebicka, Christian P. Strassburg, Ulrich Spengler, Diana Julie Leeming, Aleksander Krag, Søren Møller, Evrim Anadol, Mette Juul Nielsen, Inger Byrjalsen, Flemming Bendtsen, Robert Schierwagen, Jürgen K. Rockstroh, Carolyn Schwarzer-Zander
Publikováno v:
Leeming, D J, Anadol, E, Schierwagen, R, Karsdal, M A, Byrjalsen, I, Nielsen, M J, Schwarzer-Zander, C, Boesecke, C, Bendtsen, F, Møller, S, Strassburg, C P, Spengler, U, Krag, A, Rockstroh, J & Trebicka, J K 2014, ' Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers ', AIDS, vol. 28, no. 14, pp. 2081-2090 . https://doi.org/10.1097/QAD.0000000000000388
OBJECTIVES: Combined antiretroviral therapy (cART) attenuates hepatic fibrosis in hepatitis C virus and HIV coinfected patients. However, the role of HIV or cART on hepatic fibrosis in HIV monoinfection is discussed controversially. During liver fibr
Autor:
M Eisenhardt, Benjamin Krämer, Christoph Boesecke, Ulrich Spengler, Andreas Glässner, Jacob Nattermann, P Kokordelis, Jürgen K. Rockstroh, Hans-Dieter Nischalke, F Wolter
Publikováno v:
AIDS. 28:1879-1884
Objective The objective of this study was to analyse the potential role of CD27 in natural killer (NK) cell-mediated control of hepatitis C virus (HCV) infection in HIV-positive patients. Design Frequency of CD27-expressing CD56 NK cells was analysed
Autor:
Mattias Mandorfer, Robert Zangerle, Christoph Boesecke, Markus Peck-Radosavljevic, Antonio Rivero, Dirk Meyer-Olson, Jürgen K. Rockstroh, Karin Neukam, Massimo Puoti, Berit A. Payer, Thomas Reiberger, Michael Trauner, Anna Grzeszczuk, Axel Baumgarten, Juan A. Pineda
Publikováno v:
AIDS. 27:2707-2714
OBJECTIVE According to the European AIDS Clinical Society (EACS) guidelines for response-guided therapy (RGT) of chronic hepatitis C virus (HCV) infection in HIV-positive patients, HCV-genotype (GT) and rapid virologic response (RVR) exclusively dete
Autor:
Jürgen K. Rockstroh, Clifford Leen, Andrzej Horban, Stéphane De Wit, Vincent Soriano, Daniel Grint, Eva Poveda, Lars Peters, Jens D Lundgren, Francisco Antunes, Antonella d'Arminio Monforte
Publikováno v:
AIDS. 25:1987-1992
Background: Hepatitisdelta virus(HDV) infection resultsin the mostaggressive formof chronic viral hepatitis. There is scarce information about the prevalence, epidemiology, virological profile and natural history of hepatitis delta in HIV patients. M
Autor:
Hedy Teppler, Randi Y. Leavitt, Michael D. Miller, Kim M. Strohmaier, Jürgen K. Rockstroh, Jing Zhao, Bach-Yen Nguyen, Charlotte M. Harvey, Peter Sklar
Publikováno v:
AIDS. 25:1365-1369
Objective: We evaluated the long-term efficacy of raltegravir according to HIV-1 subtype (B and non-B) using data from three phase III studies in treatment-experienced (BENCHMRK-1 and 2) and treatment-naive (STARTMRK) HIV-infected patients. Methods:
Autor:
Bonaventura Clotet, Jacqueline Neuhaus, Vicente Soriano, Lars Peters, Bernd Kupfer, Massimo Puoti, Gregory J. Dore, Jürgen K. Rockstroh, Amanda Mocroft, Marina B. Klein, Jens D Lundgren, Ellen Tedaldi
Publikováno v:
AIDS. 24:857-865
BACKGROUND: The impact of antiretroviral therapy (ART) interruption in HIV-hepatitis B virus (HBV)-coinfected patients was examined in the Strategic Management of AntiRetroviral Therapy (SMART) study. METHODS: Plasma HBV DNA was measured in all hepat
Autor:
Jürgen K. Rockstroh, M. Michalk, Golo Ahlenstiel, Jacob Nattermann, Ulrich Spengler, Tilman Sauerbruch, Mark Danta, Martin Vogel, Hans Dieter Nischalke
Publikováno v:
AIDS. 22:1287-1292
BACKGROUND Coinfection with the hepatitis C virus (HCV) in HIV-positive patients is an emerging health problem. The factors affecting response to HCV-specific therapy are poorly understood but may involve host genetic factors. HCV NS5A-induced inhibi
Autor:
Patrick Yeni, N. Vetter, Beatriz Grinsztejn, José M. Gatell, Wim Louis Julien Parys, Albrecht Stoehr, Anton Pozniak, Jürgen K. Rockstroh, Tony Vangeneugden, Roberto Esposito, Jean-Christophe Goffard, Christine Katlama
Publikováno v:
AIDS. 21:395-402
BACKGROUND The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients. DESIGN This randomized, partially blinded, 24-w